The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
04 2019
Historique:
received: 24 10 2018
accepted: 19 03 2019
entrez: 13 4 2019
pubmed: 13 4 2019
medline: 28 11 2019
Statut: epublish

Résumé

Most pregnancy hypertension estimates in less-developed countries are from cross-sectional hospital surveys and are considered overestimates. We estimated population-based rates by standardised methods in 27 intervention clusters of the Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials. CLIP-eligible pregnant women identified in their homes or local primary health centres (2013-2017). Included here are women who had delivered by trial end and received a visit from a community health worker trained to provide supplementary hypertension-oriented care, including standardised blood pressure (BP) measurement. Hypertension (BP ≥ 140/90 mm Hg) was defined as chronic (first detected at <20 weeks gestation) or gestational (≥20 weeks); pre-eclampsia was gestational hypertension plus proteinuria or a pre-eclampsia-defining complication. A multi-level regression model compared hypertension rates and types between countries (p < 0.05 considered significant). In 28,420 pregnancies studied, women were usually young (median age 23-28 years), parous (53.7%-77.3%), with singletons (≥97.5%), and enrolled at a median gestational age of 10.4 (India) to 25.9 weeks (Mozambique). Basic education varied (22.8% in Pakistan to 57.9% in India). Pregnancy hypertension incidence was lower in Pakistan (9.3%) than India (10.3%), Mozambique (10.9%), or Nigeria (10.2%) (p = 0.001). Most hypertension was diastolic only (46.4% in India, 72.7% in Pakistan, 61.3% in Mozambique, and 63.3% in Nigeria). At first presentation with elevated BP, gestational hypertension was most common diagnosis (particularly in Mozambique [8.4%] versus India [6.9%], Pakistan [6.5%], and Nigeria [7.1%]; p < 0.001), followed by pre-eclampsia (India [3.8%], Nigeria [3.0%], Pakistan [2.4%], and Mozambique [2.3%]; p < 0.001) and chronic hypertension (especially in Mozambique [2.5%] and Nigeria [2.8%], compared with India [1.2%] and Pakistan [1.5%]; p < 0.001). Inclusion of additional diagnoses of hypertension and related complications, from household surveys or facility record review (unavailable in Nigeria), revealed higher hypertension incidence: 14.0% in India, 11.6% in Pakistan, and 16.8% in Mozambique; eclampsia was rare (<0.5%). Pregnancy hypertension is common in less-developed settings. Most women in this study presented with gestational hypertension amenable to surveillance and timed delivery to improve outcomes. This study is a secondary analysis of a clinical trial - ClinicalTrials.gov registration number NCT01911494.

Sections du résumé

BACKGROUND
Most pregnancy hypertension estimates in less-developed countries are from cross-sectional hospital surveys and are considered overestimates. We estimated population-based rates by standardised methods in 27 intervention clusters of the Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials.
METHODS AND FINDINGS
CLIP-eligible pregnant women identified in their homes or local primary health centres (2013-2017). Included here are women who had delivered by trial end and received a visit from a community health worker trained to provide supplementary hypertension-oriented care, including standardised blood pressure (BP) measurement. Hypertension (BP ≥ 140/90 mm Hg) was defined as chronic (first detected at <20 weeks gestation) or gestational (≥20 weeks); pre-eclampsia was gestational hypertension plus proteinuria or a pre-eclampsia-defining complication. A multi-level regression model compared hypertension rates and types between countries (p < 0.05 considered significant). In 28,420 pregnancies studied, women were usually young (median age 23-28 years), parous (53.7%-77.3%), with singletons (≥97.5%), and enrolled at a median gestational age of 10.4 (India) to 25.9 weeks (Mozambique). Basic education varied (22.8% in Pakistan to 57.9% in India). Pregnancy hypertension incidence was lower in Pakistan (9.3%) than India (10.3%), Mozambique (10.9%), or Nigeria (10.2%) (p = 0.001). Most hypertension was diastolic only (46.4% in India, 72.7% in Pakistan, 61.3% in Mozambique, and 63.3% in Nigeria). At first presentation with elevated BP, gestational hypertension was most common diagnosis (particularly in Mozambique [8.4%] versus India [6.9%], Pakistan [6.5%], and Nigeria [7.1%]; p < 0.001), followed by pre-eclampsia (India [3.8%], Nigeria [3.0%], Pakistan [2.4%], and Mozambique [2.3%]; p < 0.001) and chronic hypertension (especially in Mozambique [2.5%] and Nigeria [2.8%], compared with India [1.2%] and Pakistan [1.5%]; p < 0.001). Inclusion of additional diagnoses of hypertension and related complications, from household surveys or facility record review (unavailable in Nigeria), revealed higher hypertension incidence: 14.0% in India, 11.6% in Pakistan, and 16.8% in Mozambique; eclampsia was rare (<0.5%).
CONCLUSIONS
Pregnancy hypertension is common in less-developed settings. Most women in this study presented with gestational hypertension amenable to surveillance and timed delivery to improve outcomes.
TRIAL REGISTRATION
This study is a secondary analysis of a clinical trial - ClinicalTrials.gov registration number NCT01911494.

Identifiants

pubmed: 30978179
doi: 10.1371/journal.pmed.1002783
pii: PMEDICINE-D-18-03646
pmc: PMC6461222
doi:

Banques de données

ClinicalTrials.gov
['NCT01911494']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1002783

Investigateurs

Jeffrey Bone (JB)
Jing Li (JL)
Domena K Tu (DKT)

Déclaration de conflit d'intérêts

I have read the journal's policy and the authors of this manuscript have the following competing interests: ZAB is a member of the Editorial Board of PLOS Medicine.

Références

BMC Pregnancy Childbirth. 2014 Feb 27;14:90
pubmed: 24576205
Am J Obstet Gynecol. 2012 Jun;206(6):470-5
pubmed: 21963308
BMC Pregnancy Childbirth. 2018 Jan 18;18(1):34
pubmed: 29347927
J Natl Med Assoc. 2004 Dec;96(12):1626-31
pubmed: 15622693
Aust N Z J Obstet Gynaecol. 2010 Feb;50(1):40-4
pubmed: 20218996
Ann Cardiol Angeiol (Paris). 2014 Jun;63(3):145-50
pubmed: 24951092
Can J Cardiol. 2012 May;28(3):270-87
pubmed: 22595447
Int J Gynaecol Obstet. 2012 Sep;118(3):190-3
pubmed: 22738806
Obstet Gynecol Surv. 2017 Apr;72(4):248-252
pubmed: 28426127
N Engl J Med. 2015 Jan 29;372(5):407-17
pubmed: 25629739
BJOG. 2014 Mar;121 Suppl 1:14-24
pubmed: 24641531
Lancet. 2016 Oct 29;388(10056):2164-2175
pubmed: 27642022
JMIR Mhealth Uhealth. 2015 Apr 17;3(2):e37
pubmed: 25887292
Lancet. 2014 Sep 13;384(9947):980-1004
pubmed: 24797575
Blood Press Monit. 2015 Feb;20(1):52-5
pubmed: 25243711
BJOG. 2016 May;123(6):928-38
pubmed: 25974281
Hypertens Pregnancy. 2012;31(1):120-30
pubmed: 21219122
J Obstet Gynaecol Can. 2015 Jan;37(1):16-24
pubmed: 25764032
PLoS One. 2014 Dec 01;9(12):e113715
pubmed: 25436639
Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):1-7
pubmed: 23746796
J Ayub Med Coll Abbottabad. 2014 Oct-Dec;26(4):518-21
pubmed: 25672178
Pregnancy Hypertens. 2018 Jul;13:291-310
pubmed: 29803330
PLoS Med. 2014 Jan;11(1):e1001589
pubmed: 24465185
IEEE J Biomed Health Inform. 2014 Nov;18(6):1857-64
pubmed: 25375683
BMC Pregnancy Childbirth. 2015 Feb 03;15:7
pubmed: 25645738
Glob Heart. 2013 Mar;8(1):49-57
pubmed: 25690263

Auteurs

Laura A Magee (LA)

School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Sumedha Sharma (S)

Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada.

Hannah L Nathan (HL)

School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Olalekan O Adetoro (OO)

Olabisi Onabanjo University, Ago Iwoye, Ogun State, Nigeria.

Mrutynjaya B Bellad (MB)

Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India.

Shivaprasad Goudar (S)

Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India.

Salécio E Macuacua (SE)

Centro de Investigação em Saúde da Manhiça, Manhiça, Mozambique.

Ashalata Mallapur (A)

S Nijalingappa Medical College, Hanagal Shree Kumareshwar Hospital and Research Centre, Bagalkote, Karnataka, India.

Rahat Qureshi (R)

Centre of Excellence, Division of Woman and Child Health, Aga Khan University, Karachi, Pakistan.

Esperança Sevene (E)

Centro de Investigação em Saúde da Manhiça, Manhiça, Mozambique.

John Sotunsa (J)

Babcock University Teaching Hospital, Ilishan-Remo, Ogun State, Nigeria.

Anifa Valá (A)

Centro de Investigação em Saúde da Manhiça, Manhiça, Mozambique.

Tang Lee (T)

Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada.

Beth A Payne (BA)

Centre for International Child Health, University of British Columbia, Vancouver, British Columbia, Canada.

Marianne Vidler (M)

Centre for International Child Health, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Global Child Health, Hospital for Sick Children, Toronto, Ontario, Canada.

Andrew H Shennan (AH)

School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Zulfiqar A Bhutta (ZA)

Centre of Excellence, Division of Woman and Child Health, Aga Khan University, Karachi, Pakistan.
Centre for Global Child Health, Hospital for Sick Children, Toronto, Ontario, Canada.

Peter von Dadelszen (P)

School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH